Skip to main content
Premium Trial:

Request an Annual Quote

Genomind Closes on $5M Financing

NEW YORK (GenomeWeb News) – Genomind, a firm developing genetic tests focused on psychiatry and neurology, announced today the closing of a $5 million financing round.

Claritas Capital led the round, which will be used to grow Chalfont, Penn.-based Genomind and its product portfolio. Its lead test is the Genecept Assay, a saliva-based test that assesses ten genes to help clinicians make treatment decisions for patients with depression and other psychiatric disorders. With today's funding, the company plans to increase adoption of the test, Genomind CEO Ronald Dozoretz said.

In November, Genomind also announced it acquired the exclusive rights from Emory University to commercialize blood-based protein biomarkers for assessing mild cognitive impairment and Alzheimer's disease.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.